论文部分内容阅读
目的:研究利福喷丁与利福平用于肺结核治疗中的效果和安全性。方法:在我院于2014年10月-2016年6月间收治的肺结核患者中随机抽取出150例为研究对象,根据治疗方法的不同进行分组,A组患者给予利福喷丁治疗,B组患者给予利福平治疗,统计分析两组患者的治疗总有效率、不良反应发生率。结果:A组患者的治疗总有效率96%比对照组患者的86.67%高,P<0.05;A组患者不良反应发生率5.33%低于B组的16.0%,P<0.05。结论:在肺结核的临床治疗中,利福喷丁的应用能取得更好的治疗效果,且用药安全性高,患者耐受性好,值得在临床治疗中推广应用。
Objective: To study the efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis. Methods: A total of 150 patients with tuberculosis were enrolled in our hospital from October 2014 to June 2016. The patients were divided into groups according to the different treatment methods. Group A received rifapentine, while group B Patients given rifampicin treatment, statistical analysis of the two groups of patients with total effective rate of treatment, the incidence of adverse reactions. Results: The total effective rate in group A was 96% higher than that in control group (86.67%, P <0.05). The incidence of adverse reactions in group A was lower than that in group B (5.33%, P <0.05). Conclusion: In the clinical treatment of tuberculosis, the application of rifapentine can achieve better therapeutic effect, and the medication is safe and the patient is well tolerated, so it is worth to be popularized and applied in clinical treatment.